A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients

Blood Pressure

Volumn 20, Issue 6, 2011, Pages 322-334

  Garcia Donaire J A ^a   Segura, J ^a   Cerezo, C ^a   Ruilope, L M ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

cardiovascular risk; hypertension; proteinuria; renal disease; reninangiotensinaldosterone system; type 2 diabetes

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIURETIC AGENT; DOXAZOSIN; HYDROCHLOROTHIAZIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT;

ALBUMINURIA; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC PATIENT; DRUG WITHDRAWAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; REVIEW; SIDE EFFECT; STROKE; TREATMENT OUTCOME;

ALBUMINURIA; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; EUROPE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KIDNEY DISEASES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 81255165763     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.3109/08037051.2011.602878     Document Type: Review

References (80)

1. Plantinga LC, Crews DC, Coresh J, MIller ER 3rd, Saran R, Yee J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol. 2010;5:673-682.
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154-2169.
3. Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol. 2007;2:581-590.
4. McCullough PA, Li S, Jurkovitz CT, Stevens L, Collins AJ, Chen SC, et al. Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. Am Heart J. 2008;156:277-283.
5. Agrawal V, Marinescu V, Agarwal M, McCullough PA. Cardiovascular implications of proteinuria: An indicator of chronic kidney disease. Nat Rev Cardiol. 2009;6:301-311.
6. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular fi ltration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet. 2010; 375:2073-2081.
7. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-1536.
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 28. BMJ. 1998; 317:703-713.
9. UK Prospective Diabetes Study Group. Effi cacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ. 1998;317:713-720.
10. Holman RH, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008;359:1565-1576.
11. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611-616.
12. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A; CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on fi rst-line therapy with an ACE inhibitor compared with a diuretic/beta-blockerbased treatment regimen: A subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24:2091-2096.
13. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
14. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355: 253-259.
15. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S; Hope Investigators. Renal insuffi ciency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med. 2001;134:629-636.
16. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
17. Berthet K, Neal BC, Chalmers JP, MacMahon SW, Bousser MG, Colman SA, et al. Reductions in the risks of recurrent stroke in patients with and without diabetes: The PROGRESS Trial. Blood Press. 2004;13:7-13.
18. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995-1003.
19. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002;359:1004-1010.
20. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care. 2006;29:595-600.
21. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes. J Nephrol. 2008;21:566-569.
22. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007 Jan 24:(1):CD002003.
23. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: Is it a wise choice? Lancet. 2004;364:1684-1689.
24. Mason JM, Dickinson HO, Nicolson DJ, Campbell F, Ford GA, Williams B. The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens. 2005;23:1777-1781.
25. Blackburn DF, Wilson TW. Antihypertensive medications and blood sugar: Theories and implications. Can J Cardiol. 2006; 22:229-233.
26. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med. 2000;342:905-912.
27. ALLHAT Offi cers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in highrisk hypertensive patients randomized to angiotensinconverting- enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
28. Davis BR, Furberg CD, Wright JT, Cutler JA, Whelton P; ALLHAT Collaborative Research Group. ALLHAT: Setting the record straight. Ann Intern Med. 2004;141:39-46.
29. Wright JT, Probstfi eld JL, Cushman WC, Pressel S, Cutler JA, Davis BR, et al. ALLHAT fi ndings revisited in the context of subsequent analyses, other trials and meta-analyses. Arch Intern Med. 209;169:832-842.
30. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283:1967-1975.
31. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as fi rst-step antihypertensive therapy: Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239-246.
32. Hollenberg NK, Epstein M. Renin angiotensin system blockade and nephropathy: Why is it being called into question, and should it be? Clin J Am Soc Nephrol. 2006;1:1046-1048.
33. Messerli FH. ALLHAT, or the soft science of the secondary end point. Ann Intern Med. 2003;139:777-780.
34. Sierra C, Ruilope LM. New-onset diabetes and antihypertensive therapy: Comments on ALLHAT trial. J Renin Angiotensin Aldosterone Syst. 2003;4:169-170.
35. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment. Arch Intern Med. 2006;166:2191-2201.
36. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm and the relative infl uence of antihypertensive medication. Diabetes Care. 2008;31:982-988.
37. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet. 2007;369:201-207.
38. Carter BL, Einhorn PT, Brands M, He J, Cutler JA, Whelton PK, et al. Thiazide-induced dysglycemia: Call for research from a working group from the National Heart, Lung, and Blood Institute. Hypertension. 2008;52:30-36.
39. Shafi T, Appel LJ, Miller ER 3rd, Klag MJ, Parekh RS. Changes in serum potassium mediate thiazide-induced diabetes. Hypertension. 2008;52:1022-1029.
40. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: A quantitative revue. Hypertension. 2006;48:219-224.
41. Agarwal R. Hypertension, hyperkalemia, and thiazide-induced diabetes: A 3-way connection. Hypertension. 2008; 52:1012-1013.
42. Dronavalli S, Bakris GL. Mechanistic insights into diureticinduced insulin resistance. Hypertension. 2008;52:1009-1011.
43. Eriksson JW, Jansson PA, Carlberg B, Häg g A, Kurland L, Svensson MK. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: The mechanisms for the diabetes preventing effect of candesartan (MEDICA) study. Hypertension. 2008;52:1030-1037.
44. Zhou MS, Schulman IH, Jaimes EA, Raij L. Thiazide diuretics, endothelial function, and vascular oxidative stress. J Hypertens. 2008;26:494-500.
45. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafi dis P, Fakouhi K, et al. Differences in glucose tolerance between fi xeddose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006;29:2592-2597.
46. Perneger TV, Brancati FL, Whelton PK, Klag MJ. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med. 1994;121:912-918.
47. Bakris GL, Ritz E; World Kidney Day Steering Committee. The message for World Kidney Day 2009: Hypertension and kidney disease - a marriage that should be prevented. J Hypertens. 2009;27:666-669.
48. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS Group. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63: 225-232.
49. McCullough PA, Verrill TA. Cardiorenal interaction: Appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med. 2010;122:25-34.
50. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. BMJ. 2004;329:828. Epub 2004 Sep 30.
51. Strippoli GF, Craig M, Schena FP, Craig JC. Antihypertensive agents for primary prevention of diabetic nephropathy. J Am Soc Nephrol. 2005;16:3081-3091.
52. Strippoli GF, Craig M, Craig JC. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD004136.
53. Strippoli GF, Craig M, Schena FP, Craig JC. Role of blood pressure targets and specifi c antihypertensive agents used to prevent diabetic nephropathy and delay its progression. J Am Soc Nephrol. 2006;17(4 Suppl 2):S153-S155.
54. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006257.
55. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
56. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345;861-869.
57. Parving HH, Lehnert H, Bröc hner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
58. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin- converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008;372:1174-1183.
59. Bilous R, Chaturvedi N, Sjø l ie AK, Fuller J, Klein R, Orchard T, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: Three randomized trials. Ann Intern Med. 2009;151:11-20.
60. Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907-917.
61. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
62. ADVANCE Collaborative Group. Effects of a fi xed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): A randomised controlled trial. Lancet. 2007;370:829-840.
63. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359: 2417-2428.
64. ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362: 1575-1585.
65. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138:542-549.
66. Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, et al. Effect of telmisartan on renal outcomes: A randomised trial. Ann Intern Med. 2009;151:1-10.
67. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on prevention (DIRECTPrevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: Randomised, placebo-controlled trials. Lancet. 2008;372:1394-1402.
68. Sj øl ie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, et al. Effect of candesartan on regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): A randomised placebo- controlled trial. Lancet. 2008;372:1385-1393.
69. Bertrand ME, Mourad JJ. Reduction in mortality with antihypertensive agents. Evidence from clinical trials in at-risk hypertensive patients. Eur Heart J. 2010;31(Abstr Suppl):321-322 [Abstract 2019].
70. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfi eld M. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendrofl umethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial- Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366:895-906.
71. Beckett NS, Peters NS, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887-1898.
72. Mann JF, Schmeider RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547-553.
73. de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883-892.
74. Lambers Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S, Cass A, et al. Effects of a fi xed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J. 2010;31: 2888-2896.
75. Su DC, Kim CM, Choi IS, Plauschinat CA, Barone JA. Trends in blood pressure control and treatment among type 2 diabetes with comorbid hypertension in the United States: 1988 - 2004. J Hypertens. 2009;27:1908-1918.
76. Bakris GL, Sarafi dis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al. Renal outcomes with different fi xed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): A prespecifi ed secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173-1181.
77. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010; 56:77-85.
78. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfi eld MJ, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens. 2009;27: 2121-2158.
79. Jerums G, Panagiotopoulos S, Premaratne E, Power DA, MacIsaac RJ. Lowering of proteinuria in response to antihypertensive therapy predicts improved renal function in late but not in early diabetic nephropathy: A pooled analysis. Am J Nephrol. 2008;28:614-627.
80. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, et al. Proteinuria as a surrogate outcome in CKD: Report of a scientifi c workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2009;54:205-226.